Bhide NS, Dickinson S, Feinberg E, Mohamed M, Dupre K, Eskow-Jaunarajs K, Lindenbach D, Ostock C, Bishop C (2011) Norepinephrine denervation by dopamine beta-hydroxylase saporin impacts L-DOPA efficacy and side effects in a hemi-parkinsonian rat model. Neuroscience 2011 Abstracts 883.20. Society for Neuroscience, Washington, DC.
Summary: Dopaminergic neurodegeneration in Parkinson’s disease (PD) is accompanied by concomitant loss in the norepinephrine (NE) system. The exact contribution of NE denervation in the development of PD remains elusive. Recently, we demonstrated that NE neurons may contribute to the efficacy and side effects of L-DOPA, however, to better mimic NE loss observed in PD we employed the selective NE neurotoxin dopamine beta hydroxylase saporin (DHB saporin) and evaluated its effects on the anti-parkinsonian efficacy of L-DOPA and the development & expression of L-DOPA induced dyskinesia (LID). To do so, hemiparkinsonian adult Sprague-Dawley rats were exposed to intraventricular injections of either vehicle or DHB saporin. Three weeks later, animals were primed with L-DOPA (4mg/kg) for days 1-7 and L-DOPA (12 mg/kg) for days 9-15. During this period animals were monitored for motor-performance, a marker for L-DOPA’s anti-parkinsonian efficacy, and dyskinesia measured using Abnormal Involuntary Movements (AIMs) scale. Further, sensitivity of primed animals to different doses of L-DOPA (ranging from 2 to 12 mg/kg) was assessed. Results indicate that NE denervation resulted in reduced anti-parkinsonian efficacy of L-DOPA, but not the development of dyskinesia. In fully primed rats, NE denervation attenuated dyskinetic responses to L-DOPA when compared to animals with an intact NE innervation. These findings suggest that the NE system significantly modulates the anti-parkinsonian effects of L-DOPA and the expression of LID and indicate the importance of understanding the mechanisms by which NE modifies basal ganglia function in PD.
Related Products: Anti-DBH-SAP (Cat. #IT-03)